A novel nucleic acid analogue shows strong angiogenic activity

Biochemical and Biophysical Research Communications

Volumn 399, Issue 4, 2010, Pages 699-704

  Tsukamoto, Ikuko ^a   Sakakibara, Norikazu ^b   Maruyama, Tokumi ^b   Igarashi, Junsuke ^a   Kosaka, Hiroaki ^a   Kubota, Yasuo ^a   Tokuda, Masaaki ^a   Ashino, Hiromi ^c   Hattori, Kenichi ^d   Tanaka, Shinji ^d   Kawata, Mitsuhiro ^d   Konishi, Ryoji ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^d Teikoku Seiyaku Co Ltd   (Japan)

Author keywords

Angiogenesis stimulator; Chorioallantoic membrane assay; Corneal micropocket assay; ERK1 2 activation; HUVEC; MAP kinase cascade; Nucleic acid analogue; Tube formation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2CL C OXT A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RNA DERIVATIVE; UNCLASSIFIED DRUG; 2CL-C.OXT-A; ADENOSINE; ANGIOGENIC FACTOR; NUCLEIC ACID;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; CORNACEAE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MECHANICAL PROBE; NONHUMAN; PRIORITY JOURNAL; UMBILICUS; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; PHYSIOLOGY; RABBIT;

ADENOSINE; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; NUCLEIC ACIDS; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 77956268584     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.003     Document Type: Article

References (26)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
2. Wong M.L.H., Prawira A., Kaye A.H., Hovens C.M. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J. Clin. Neurosci. 2009, 16:1119-1130.
3. Makrilia N., Lappa T., Xyla V., Nikolaidis I., Syrigos K. The role of angiogenesis in solid tumours: an overview. Eur. J. Intern. Med. 2009, 20:663-671.
4. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 2005, 333:328-335.
5. D'amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 1994, 91:4082-4085.
6. Rajkumar S.V., Witzig T.E. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat. Rev. 2000, 26:351-362.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
8. Bobek V., Taltynov O., Pinterova D., Kolostova K. Gene therapy of the ischemic lower limb - therapeutic angiogenesis. Vasc. Pharmacol. 2006, 44:395-405.
9. Collinson D.J., Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?. Eur. J. Vasc. Endovasc. Surg. 2004, 28:9-23.
10. O'Toole G., MacKenzie D., Buckley M.F., Linderman R., Poole M. A review of therapeutic angiogenesis and consideration of its potential applications to plastic and reconstructive surgery. Br. J. Plast. Surg. 2001, 54:1-7.
11. Cho K.R., Choi J.-S., Hahn W., Kim D.S., Park J.S., Lee D.S., Kim K.-B. Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur. J. Cardiothorac. Surg. 2008, 34:857-863.
12. Nagai K., Matsumaru I., Fukushima T., Miyazaki Y., Yamaguchi H., Kamihira S., Eishi K., Tomonaga M. Therapeutic angiogenesis by autologous transplantation of bone marrow mononuclear cells for peripheral artery disease. Int. Congress Ser. 2007, 1299:203-209.
13. Rajagopalan S., Mohler E., Lederman R.J., Saucedo J., Mendelsohn F.O., Olin J., Blebea J., Goldman C., Trachtenberg J.D., Pressler M., Rasmussen H., Annex B.H., Hirsch A.T. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am. Heart J. 2003, 145:1114-1118.
14. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., Hillegass W.B., Rocha-Singh K., Moon T.E., Whitehouse M.J., Annex B.H. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002, 359:2053-2058.
15. Auerbach R., Lewis R., Shinners B., Kubai L., Akhtar N. Angiogenesis assays: a critical overview. Clin. Chem. 2003, 49:32-40.
16. Basacchi G.S., Braitman A., Cianci C.W., Clark J.M., Field A.K., Hagen M.E., Hockstein D.R., Malley M.F., Mitt T., Slusarchyk W.A., Sundeen J.E., Terry B.J., Tuomari A.V., Weaver E.R., Young M.G., Zahler R. Synthesis and antiviral activity of enantiomeric forms of cyclobutyl nucleoside analogs. J. Med. Chem. 1991, 34:1415-1421.
17. Lu H., Murtagh J., Schwartz E.L. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol. Pharmacol. 2006, 69:1207-1215.
18. Igarashi J., Shoji K., Hashimoto T., Moriue T., Yoneda K., Takamura T., Yamashhita T., Kubota Y., Kosaka H. Transforming growth factor-β1 downregulates caveolin-1 expression and enhances sphingosine 1-phosphate signaling in cultured vascular endothelial cells. Am. J. Physiol. Cell Physiol. 2009, 297:C1263-C1274.
19. Igarashi J., Miyoshi M., Hashimoto T., Kubota Y., Kosaka H. Hydrogen peroxide induces S1P1 receptors and sensitizes vascular endothelial cells to sphingosine 1-phosphate, a platelet-derived lipid mediator. Am. J. Physiol. Cell Physiol. 2007, 292:C740-C748.
20. Igarashi J., Miyoshi M., Hashimoto T., Kubota Y., Kosaka H. Statins induce S1P(1) receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol. 2007, 150:470-479.
21. Ashino H., Shimamura M., Nakajima H., Dombou M., Kawanaka S., Oikawa T., Iwaguchi T., Kawashima S. Novel function of ascorbic acid as an angiostatic factor. Angiogenesis 2003, 6:259-269.
22. Kato T., Kure T., Chang J.-H., Gabison E.E., Itoh T., Itohara S., Azar D.T. Diminished corneal angiogenesis in gelatinase A-de¢cient mice. FEBS Lett. 2001, 508:187-190.
23. Yonesu K., Kawase Y., Inoue T., Takagi N., Tsuchida J., Takuwa Y., Kumakura S., Nara F. Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog. Biochem. Pharmacol. 2009, 77:1011-1020.
24. Grünewald F.S., Prota A.E., Giese A., Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim. Biophys. Acta 2010, 1804:567-580.
25. Takahashi1 T., Ueno H., Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999, 18:2221-2230.
26. Fong T.A.T., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K.P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59:99-106.